ANRO (Alto Neuroscience) Tariff Resilience Score: 5/10 (As of Jul. 03, 2026)


ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $24.78
! 1 Warning Sign
View Full Analysis

What is Alto Neuroscience Tariff Resilience Score?

Alto Neuroscience ANRO -0.64% 12 Tariff Resilience Score is 5 as of Jul. 03, 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,373 Biotechnology companies, Alto Neuroscience ranks better than 62.27% on this metric.

Alto Neuroscience has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Alto Neuroscience has Alto Neuroscience Inc relies on imported components for its neuroscience products, exposing it to tariff risks. The company has limited pricing power but is exploring alternative suppliers to mitigate potential impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Alto Neuroscience might have Average Resilient.

Alto Neuroscience  (NYSE:ANRO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Alto Neuroscience Tariff Resilience Score Related Terms

ANRO vs SANA, AVTX, REPL: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Alto Neuroscience's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Tariff Resilience Score falls into.


ANRO
12GF Score
Alto Neuroscience Inc ANRO
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Alto Neuroscience (ANRO) has a Tariff Resilience Score of 5 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Alto Neuroscience ranks #518 out of 1373 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Alto Neuroscience's Tariff Resilience Score too high?
Alto Neuroscience's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Alto Neuroscience's value of 5 is 25% above this industry median. Based on the distribution chart, Alto Neuroscience ranks #518 out of 1373 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Tariff Resilience Score compare to SANA and AVTX?
According to the Biotechnology industry distribution chart, Alto Neuroscience ranks #518 out of 1373 companies for Tariff Resilience Score. This puts Alto Neuroscience in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Alto Neuroscience's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alto Neuroscience's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alto Neuroscience's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Alto Neuroscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Tariff Resilience Score is 5 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.78
Price